Preventing and controlling influenza virus infection remains a global public health
challenge, as it causes seasonal epidemics to unexpected pandemics. These infections are …

Global analysis of the susceptibility of influenza viruses to neuraminidase (NA) inhibitors
(NAIs) and the polymerase acidic (PA) inhibitor (PAI) baloxavir was conducted by five World …

Influenza A and B viruses are among the most prominent human respiratory pathogens.
About 3–5 million severe cases of influenza are associated with 300 000–650 000 deaths …

Influenza virus is a highly contagious zoonotic respiratory disease that causes seasonal
outbreaks each year and unpredictable pandemics occasionally with high morbidity and …

It is more than 20 years since the neuraminidase inhibitors, oseltamivir and zanamivir were
approved for the treatment and prevention of influenza. Guidelines for global surveillance …

Baloxavir marboxil (BXM) is approved for treating uncomplicated influenza. The active
metabolite baloxavir acid (BXA) inhibits cap-dependent endonuclease activity of the …

Background Recent outbreaks of avian influenza and ongoing virus reassortment have
drawn focus on spill-over infections. The increase in human infections with highly …

Baloxavir marboxil (baloxavir) is a recently FDA-approved influenza virus polymerase acidic
(PA) endonuclease inhibitor. Several PA substitutions have been demonstrated to confer …

Baloxavir marboxil (BXM) treatment-emergent polymerase acid (PA) I38X amino acid
substitution (AAS) in the resistant variants of influenza viruses raise concerns regarding their …

Despite considerable progress in the development of antiviral drugs, among which anti-
immunodeficiency virus (HIV) and anti-hepatitis C virus (HCV) medications can be …